| Field | Specification |
|---|---|
| Alternative names | Tetrahydroxy-1,4-benzoquinone monohydrate; Tetrahydroxybenzoquinone monohydrate |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C6H6O7 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Tetrahydroxyquinone monohydrate, also known as Tetrahydroxy-1,4-benzoquinone monohydrate or Tetrahydroxybenzoquinone monohydrate, is a redox-active benzoquinone that has been studied as an early anticataract agent. It can participate in a redox cycle involving semiquinone radicals, which leads to formation of reactive oxygen species (ROS)[1]. It is supplied as a brown to black solid (C6H6O7, MW 190.11) at 97.0% purity.
Physical & Chemical Properties
| CAS Number | 1215458-51-7 |
|---|---|
| Molecular Formula | C6H6O7 |
| Molecular Weight | 190.11 g/mol |
| Purity | 97.0% |
| Appearance | Solid |
| Color | Brown to black |
| SMILES | O=C1C(O)=C(O)C(C(O)=C1O)=O.[H]O[H] |
| Signaling Pathway | Immunology/Inflammation; NF-κB; Metabolic Enzyme/Protease; Apoptosis |
| Solubility | In Vitro: DMSO: 100 mg/mL (526.01 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (526.01 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (13.15 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (13.15 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
Treatment with Tetrahydroxyquinone (100-500 μM; 24 hours; HL60 cells) is cytotoxic to HL60 leukaemia cells, with IC50 values of 20 μM by total protein content, 40 μM by phosphatase activity, and 45 μM by MTT assay. Tetrahydroxyquinone efficiently induces ROS production in HL60 leukaemia cells[1]. Tetrahydroxyquinone efficiently activates caspase 3 at concentrations above 25 μM, stimulates DNA fragmentation at the same concentration, and provokes phosphatidylserine exposure[1]. Tetrahydroxyquinone induces cytochrome c release from the mitochondria at concentrations as low as 25 μM. Tetrahydroxyquinone treatment also raises phosphorylation at Ser473 of protein kinase B (the Bad kinase for Ser112)[1].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. Adv Sci (Weinh) 2026 Mar;13(16):e13310. PMID: 41589654
